Quercetin Prevents In Vivo and In Vitro Myocardial Hypertrophy Through the Proteasome-GSK-3 Pathway.

Abstract

PURPOSE:

Quercetin, a flavonoid, has been reported to ameliorate cardiovascular diseases, such as cardiac hypertrophy. However, the mechanism is not completely understood. In this study, a mechanism related to proteasome-glycogen synthesis kinase 3 (GSK-3) was elucidated in rats and primary neonatal cardiomyocytes.

METHODS:

Rats were subjected to sham or constriction of abdominal aorta surgery groups and treated with or without quercetin for 8 weeks. Angiotensin II (Ang II)-induced primary cardiomyocytes were cultured with quercetin treatment or not for 48 h. Echocardiography, real-time RT-PCR, histology, immunofluorescence, and Western blotting were conducted. Proteasome activities were also detected using a fluorescent peptide substrate.

RESULTS:

Echocardiography showed that quercetin prevented constriction of abdominal aorta-induced cardiac hypertrophy and improved the cardiac diastolic function. In addition, quercetin also significantly reduced the Ang II-induced hypertrophic surface area and atrial natriuretic factor (ANF) mRNA level in primary cardiomyocytes. Proteasome activities were obviously inhibited in the quercetin-treated group both in vivo and in vitro. Quercetin also decreased the levels of proteasome subunit beta type (PSMB) 1, PSMB2, and PSMB5 of the 20S proteasome as well as the levels of proteasome regulatory particle (Rpt) 1 and Rpt4 of the 19S proteasome. In particular, the PSMB5 level in the nucleus was reduced after quercetin treatment. Furthermore, phosphorylated GSK-3α/β (inactivation of GSK-3) was decreased, which means that GSK-3 activity was increased. The phosphorylation levels of upstream AKT (PKB (protein kinase B)) and liver kinase B1/AMP activated protein kinase (LKB1/AMPKα) and those of downstream extracellular signal-regulated kinase (ERK), histone H3, β-catenin, and GATA binding protein 4 (GATA4) were reduced after quercetin treatment, while hypertrophy was reversed after treatment with the GSK-3 inhibitor.

CONCLUSION:

In summary, quercetin prevents cardiac hypertrophy, which is related to proteasome inhibition and activation of GSK-3α/β. Upstream (AKT, LKB1/AMPKα) and downstream hypertrophic factors, such as ERK, histone H3, β-catenin, and GATA4, may also be involved.

• Authors: Kuixiang Chen, Mubarak Rekep, Wei Wei, Qian Wu, Qin Xue, Sujuan Li, Jiahui Tian, Quan Yi, Genshui Zhang, Guiping Zhang, Qing Xiao, Jiandong Luo, Yinghua Liu
• Journal: Cardiovascular drugs and therapy (Cardiovasc Drugs Ther) Vol. 32 Issue 1 Pg. 5-21 (02 2018) ISSN: 1573-7241 [Electronic] United States
• PMID: 29435775 (Publication Type: Journal Article)

Chemical References

• Proteasome Inhibitors
• Quercetin
• Glycogen Synthase Kinase 3 beta
• Gsk3b protein, rat
• Glycogen Synthase Kinase 3
• glycogen synthase kinase 3 alpha
• Proteasome Endopeptidase Complex

Topics

• Animals
• Cells, Cultured
• Disease Models, Animal
• Glycogen Synthase Kinase 3 (metabolism)
• Glycogen Synthase Kinase 3 beta (metabolism)
• Hypertrophy, Left Ventricular (enzymology, pathology, physiopathology, prevention & control)
• Male
• Myocytes, Cardiac (drug effects, enzymology, pathology)
• Phosphorylation
• Proteasome Endopeptidase Complex (drug effects, metabolism)
• Proteasome Inhibitors (pharmacology)
• Quercetin (pharmacology)
• Rats, Sprague-Dawley
• Signal Transduction (drug effects)
• Ventricular Function, Left (drug effects)
• Ventricular Remodeling (drug effects)